Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Prim Care Companion CNS Disord ; 24(1)2022 02 03.
Article in English | MEDLINE | ID: covidwho-1674971
J Sex Marital Ther ; 48(4): 415-426, 2022.
Article in English | MEDLINE | ID: covidwho-1528058


Based on the possible effects of androgens on the course of COVID-19, it can be posited that Gender-Affirming Hormone Therapy (GAHT) may affect the course of the disease in people with GD. We aimed to investigate the relationship between GAHT and contracting COVID-19, as well as the severity of the disease in individuals with Gender Dysphoria (GD). The single center, cross-sectional, web-based survey was completed by people with GD who received GAHT. The questionnaire contained three parts: a sociodemographic data form; a GAHT data form; a COVID-19-related data form. Of the 238 participants, 179 were individuals with female-to-male (FtM) and 59 male-to-female (MtF) GD. We detected that the risk of contracting COVID-19 increased 3.46 times in people with FtM GD, who had received testosterone therapy, in comparison to people with MtF GD, who received estrogen and anti-androgen therapy. Additionally, people with FtM GD who contracted COVID-19 had received longer testosterone therapy when compared to those who did not contract COVID-19. Our findings indicate that individuals with FtM GD who receive testosterone treatment within the scope of GAHT are at higher risk of contracting COVID-19 and that the clinicians who follow-up on GAHT should be more careful about this issue.

COVID-19 , Gender Dysphoria , Transgender Persons , COVID-19/drug therapy , COVID-19/epidemiology , Cross-Sectional Studies , Female , Gender Dysphoria/therapy , Humans , Male , Testosterone/therapeutic use